Department of Defense - Armed Forces Health Surveillance Branch Integrated Biosurveillance Section - Health.mil
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Department of Defense
Armed Forces Health Surveillance Branch
Integrated Biosurveillance Section
Northeastern DRC Ebola Surveillance Summary
May 3, 2019 (next Summary May 17, 2019)
APPROVED FOR PUBLIC RELEASE
For information or assistance requests, contact AFHSB/IB at:
NIPR: dha.ncr.health-surv.list.ib-alert-response@mail.mil
DEPARTMENT OF DEFENSE (AFHSB/IB)
Northeastern DRC Ebola Surveillance Summary #31
May 3, 2019 (next Summary May 17, 2019)
CASE REPORT: From 30 APR 2018 to 1 MAY 2019, the Democratic Republic of the Congo (DRC) Ministry of Health (MOH) has reported 1,510 (+208) confirmed and
probable Ebola virus disease (EVD) cases from 21 health zones (HZs) in North Kivu and Ituri provinces in northeastern DRC (see Table for a breakdown of cases by province
and HZ). Katwa, Butembo, and Mandima HZs in North Kivu Province are the outbreak hotspots, accounting for 71% (207) of the 292 newly confirmed cases reported from 10-
30 APR. During epidemiological week (EW) 17 (week ending 27 APR), there were 126 newly confirmed cases, the highest number reported in a single EW since the outbreak
was announced in AUG 2018. There have also been 994 (+151) deaths (case fatality proportion 66%).
BACKGROUND: Persistent insecurity, population density, mobility, and community resistance continue to be compounding factors in this outbreak. As of 2 MAY, all alerts for
potential EVD cases identified outside of the DRC have been negative; however, the high level of population movement between the affected areas and neighboring countries
continues to create potential opportunities for cross-border disease transmission. As of 11 MAR 2019, WHO assesses the risk of EVD spread at the national and regional
levels as very high and the global risk as low. On 30 APR, the MOH reported that the Government of DRC had formed a multi-sectorial EVD Response Committee,
answerable to the President of the DRC, to better coordinate government responses to the EVD outbreak. On 25 APR, WHO reported community resistance and violent
attacks increased during APR in the outbreak hotspots of Katwa and Butembo, which resulted in the temporary suspension of response activities until security measures
could be enforced. On 24 APR, the MOH reported the Congolese military had arrested 11 people suspected of involvement in the 19 APR murder of a Cameroonian WHO
epidemiologist assisting in EVD response efforts in Butembo.
MEDICAL COUNTERMEASURES & DIAGNOSTICS: There have been 92 (+2) EVD cases (33 (+1) deaths) among HCWs as of 1 MAY. In late MAR, WHO infection
prevention and control (IPC) teams assessed 42 health facilities in Katwa for compliance with IPC health facility standards designed to prevent the nosocomial transmission of
EVD. The majority of facilities assessed (67%) did not meet the minimum standards to prevent nosocomial transmission, scoring the lowest in case triage, isolation, and
preventing environmental contamination.
As of 1 MAY, 108,905 (+7,316) individuals, including at least 29,000 (+3,000) children, have been vaccinated in the DRC using the investigational EVD vaccine rVSV-ZEBOV
since 8 AUG 2018. As of 26 APR, ongoing vaccination of HCWs and front-line workers (FLWs) continues in Uganda, where 4,852 have been vaccinated in at least 13
districts. As of 2 MAY, 2,050 (+195) HCWs and FLWs have been vaccinated in South Sudan. On 15 APR, vaccinations began in Rwanda, where 40 HCWs were vaccinated.
Vaccinations began in Burundi on 15 APR.
On 24 APR, WHO reported that an exercise conducted by Uganda on 11 APR to evaluate its EVD preparedness and response revealed gaps in coordination, communication,
surveillance, isolation of cases, and contact tracing. Positive findings included heightened community risk perception, indicating good community engagement and risk
communication. The Uganda MOH plans to implement a corrective action plan to address the identified shortcomings.
(+xx) represent the change in number from the previous AFHSB Surveillance Summary of 19 April 2019.
All information has been verified unless noted otherwise. For information or assistance requests, contact AFHSB/IB at:
NIPR: dha.ncr.health-surv.list.ib-alert-response@mail.mil
APPROVED FOR PUBLIC RELEASE
1
DEPARTMENT OF DEFENSE (AFHSB/IB)
Northeastern DRC Ebola Surveillance Summary #31
May 3, 2019 (next Summary May 17, 2019)
MEDICAL COUNTERMEASURES & DIAGNOSTICS (cont’d): In DRC, 11 ETUs are operational in
Beni, Bunia, Butembo, Goma, Katwa, Kayna, Komanda, Mandima, and Oicha HZs as of 28 APR. ETUs Table: Number of Confirmed and Probable EVD Cases
have also been constructed at the Bwera and Bundibugyo hospitals in western Uganda. As of 28 APR, by Province and Health Zone, 1 AUG 2018 - 1 MAY 2019
there are seven laboratories with EVD diagnostic capabilities in the affected regions of the DRC: Beni,
Bunia, Butembo, Goma, Katwa, Komanda, and Mandima. The Institut National de Recherche
Biomedicale (INRB) laboratory in Kinshasa and the laboratory in Katwa, in addition to having EVD
diagnostic capabilities, can also perform whole genomic sequencing. As of 2 MAY, recruitment
continues for a randomized controlled trial (RCT) of four investigational EVD therapeutics (mAb114,
Remdesivir, Zmapp, and REGN-3) that began enrollment on 26 NOV 2018.
TRAVEL ADVISORIES: On 9 APR, the U.S. Department of State (DoS) updated its Level 3:
Reconsider Travel alert for the DRC. The DoS has identified Eastern DRC and North Kivu and Ituri
provinces as “Do Not Travel” zones due to armed group activity, military operations, and the ongoing
EVD outbreak. On 16 APR, CDC updated its Alert – Level 2, Practice Enhanced Precautions travel
notice for EVD in the DRC, adding special guidance for U.S.-based healthcare and response workers
traveling to areas with EVD outbreaks, including recommendations to consider receiving the
investigational EVD vaccine rVSV-ZEBOV prior to travel, and to self-monitor for fever and EVD
symptoms for 21 days after leaving an outbreak area.
Source: DRC MOH
(+xx) represent the change in number from the previous AFHSB Surveillance Summary of 19 April 2019.
All information has been verified unless noted otherwise. For information or assistance requests, contact AFHSB/IB at:
NIPR: dha.ncr.health-surv.list.ib-alert-response@mail.mil
APPROVED FOR PUBLIC RELEASE
2
Text updated from the previous report will be printed in blue; items in (+xx) represent the change in number from 19 APR 2019.
All information has been verified unless noted otherwise. For information or assistance requests, contact AFHSB/IB at:
NIPR: dha.ncr.health-surv.list.ib-alert-response@mail.mil
APPROVED FOR PUBLIC RELEASE 3
You can also read
